Skip to main content

Advertisement

Table 1 Baseline demographics of treatment-naïve patients

From: Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study

Characteristic Treatment-naïve
(N = 39)
Mean (SD) age, years 68.4 (12.6)
 Range 39–88
Sex, n (%)  
 Female 21 (53.8)
 Male 18 (46.2)
Race/Ethnicity, n (%)  
 White 20 (51.3)
 Black, Asian, or other 3 (7.7)
 Not recorded in chart 16 (41.0)
Diagnosis, n (%)  
 BRVO 18 (46.2)
 CRVO 21 (53.8)
Mean (SD) duration of macular edema, months 4.9 (16.7)
 Median 1.2
 Range 0 to 105
Prior treatment for complications of retinal vein occlusion, n (%) 0 (0)
Glaucoma or ocular hypertension at baseline, n (%)  
 Yes 6 (15.4)
 No 23 (59.0)
 Not recorded in chart 10 (25.6)
Using IOP-lowering medication at baseline, n (%) 3 (7.7)
History of IOP response to steroid, n (%)  
 Yes 1 (2.6)
 No 24 (61.5)
 Not recorded in chart 14 (35.9)
Lens status, n (%)  
 Phakic 23 (59.0)
 Pseudophakic 15 (38.5)
 Not recorded 1 (2.6)
Mean (SD) BCVA, lines 8.5 (5.1)
 Snellen 20/125
Mean (SD) central retinal thickness, μm 550 (207)
  1. BCVA best-corrected visual acuity, BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, IOP intraocular pressure, SD standard deviation, VEGF vascular endothelial growth factor